Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Molecular and Cellular Biology

Abstract SY36-02: Visualizing cancer: Surgical navigation using targeted fluorescent imaging agents

Eben L. Rosenthal, Esther de Boer, Kurt Zinn, Go van Dam and Jason Warram
Eben L. Rosenthal
1Univ. of Alabama at Birmingham, Birmingham, AL;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esther de Boer
2Univeristy of Alabama at Birmingham, Birmingham, AL;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kurt Zinn
3University of Alabama at Birmingham, Birmingham, AL;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Go van Dam
4Univ. of Groningen, Groningen, Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason Warram
1Univ. of Alabama at Birmingham, Birmingham, AL;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2015-SY36-02 Published August 2015
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA

Abstract

The primary treatment for many solid cancers remains surgical resection with negative margins that requires accurate identification of cancer in real-time. Patients undergoing surgical extirpation as part of their primary or salvage treatment have an incidence of involved or close surgical margins that approaches 5-40% on histopathological review, resulting in a significantly worse outcome. Positive margin rates have not significantly changed over the past several decades because surgeons cannot successfully differentiate normal and diseased tissue using conventional evaluation methods.

Failure to identify residual disease in real-time during the surgical procedure is not surprising considering that the surgeon must rely on non-specific visual changes and manual palpation of subtle irregularities to guide successful excision. The most common method of intraoperative margin control remains frozen section analysis, however this technique is time intensive and can sample only a small fraction of the wound bed. To address the need for intraoperative cancer identification, conventional anatomical imaging modalities such as MRI and CT have been adopted for use in the operating room. Unfortunately, these are neither real-time nor tumor specific and do not allow a surgical field of view.

The field of targeted optical molecular imaging has progressed from predominantly preclinical (animal) in vivo studies towards human clinical applications. Various tumor-targeting strategies are employed in parallel to the development of imaging systems and companion fluorescent tracers. Tumor targeting methodologies include blood pool agents (indocyanine green), small peptides like ratiometric activatable penetrating peptides, folate receptor targeting, RGD-based probes, smart activatable agents that can be activated by enzymes such as matrix metalloproteinase and those based on tumor-specific receptor targeting (i.e. immuno-imaging) using (therapeutic) antibodies or smaller fragments like affibodies or nanobodies. Despite the extensive number of probes developed for in vivo use, only a handful of agents have been successfully translated for intraoperative clinical application to assess surgical margins.

Cancer-specific navigation has been successfully introduced in human glioma surgery with improvement in outcomes, but this strategy lacks specificity and applicability to other cancer types. The use of 5-ALA for glioma surgery has completed phase 3 clinical trials where it was shown to improve oncologic and functional outcomes. Although 5-ALA imaging has significant limitations for application outside of glioma surgery (dependent on a high tumor metabolic rates, possesses wavelengths with suboptimal tissue penetration), its approval in Europe and subsequent studies have demonstrated that fluorescence-based surgical navigation can be successfully applied in surgical resection. The only other in human study in optical imaging was administration of folate-fluorescein agent, which was shown to identify metastatic peritoneal disease in three out of ten patients tested. Tumor detection was limited to patients with peritoneal metastasis that had high folate receptor expression.

Adapting therapeutic antibodies for intraoperative cancer imaging leverages the known antibody safety profile to facilitate the clinical translation of the technique for surgical navigation in oncology. There have been many preclinical studies using antibodies and the first clinical studies are currently underway to assess feasibility in patients with breast cancer (Clinicaltrials.gov: NCT01508572) and colorectal cancer (Clinicaltrials.gov: NCT01972373) using fluorescently labelled bevacizumab, and head and neck cancer (Clinicaltrials.gov: NCT01987375) using cetuximab. The clinical trials have utilized both the microdosing methodology and a more conventional dose-escalation design.

The advantage of repurposing therapeutic antibodies for imaging is that the pharmacokinetic profile, biodistribution, side-effects and potential toxicity of FDA-approved antibodies are generally well-known. Moreover, the dosing of the antibodies as imaging agents is less than therapeutic levels, especially when using the microdose regimen. This makes the antibody-based approach ideal for pioneering the use of targeted imaging agents in the clinic. An additional advantage is their long half-live (days to weeks) due to the size of the protein (∼150kD), which may lead to a higher cancer specific uptake compared to smaller particles like nanobodies or peptide fragments, whose relatively fast clearance hinders bioavailability of the targeting agent. Currently, no human data exist on which moiety will emerge as the superior imaging strategy.

Over 90% of head and neck tumors are known to overexpress EGFR and therefore the fluorescently labeled cetuximab was conducted using anti-EGFR antibody. IRDye800 was used for optical labeling because previous rodent studies show a lack of toxicity, the dye is manufactured under conditions suitable for human use, and preclinical studies in non-human primates comparing cetuximab-IRDye800 to cetuximab alone showed no clinically significant toxicities. We evaluated escalating doses of cetuximab-IRDye800 in a phase I clinical trial to localize microscopic fragments of cancer during operative and pathological tumor assessment. Data from this study will be reported.

Citation Format: Eben L. Rosenthal, Esther de Boer, Kurt Zinn, Go van Dam, Jason Warram. Visualizing cancer: Surgical navigation using targeted fluorescent imaging agents. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr SY36-02. doi:10.1158/1538-7445.AM2015-SY36-02

  • ©2015 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 75 (15 Supplement)
August 2015
Volume 75, Issue 15 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract SY36-02: Visualizing cancer: Surgical navigation using targeted fluorescent imaging agents
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract SY36-02: Visualizing cancer: Surgical navigation using targeted fluorescent imaging agents
Eben L. Rosenthal, Esther de Boer, Kurt Zinn, Go van Dam and Jason Warram
Cancer Res August 1 2015 (75) (15 Supplement) SY36-02; DOI: 10.1158/1538-7445.AM2015-SY36-02

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract SY36-02: Visualizing cancer: Surgical navigation using targeted fluorescent imaging agents
Eben L. Rosenthal, Esther de Boer, Kurt Zinn, Go van Dam and Jason Warram
Cancer Res August 1 2015 (75) (15 Supplement) SY36-02; DOI: 10.1158/1538-7445.AM2015-SY36-02
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Molecular and Cellular Biology

  • Abstract RAOS15-03: Pancreatic tumor stroma as a therapeutic target
  • Abstract DDT02-01: Inhibition of the AAA-ATPase p97 with the first in class inhibitor CB-5083 as a novel approach to treat cancer
  • Abstract LB-279: Quantitative flux measurements of serum protein catabolism in PDAC and other KRAS-mutant cancers
Show more Molecular and Cellular Biology

Oral Presentations - Invited Abstracts

  • Abstract IA19: Dietary Control of Stem Cells in Physiology and Disease
  • Abstract IA20: Lymph protects metastasizing melanoma cells from ferroptosis
  • Abstract IA21: Metabolic phenotypes and liabilities in human cancer
Show more Oral Presentations - Invited Abstracts

Invited Oral Presentations - Intraoperative Imaging

  • Abstract SY36-03: Intraoperative molecular imaging with protease-activated fluorescent imaging agents
Show more Invited Oral Presentations - Intraoperative Imaging
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement